For the first time, an oral therapy has been proved to reduce the risk of developing clinically definite multiple sclerosis in patients with a clinically isolated syndrome.
Increased salt intake may magnify the risk of relapses in patients with multiple sclerosis (MS). According to researchers, excess dietary sodium intake is associated with a higher level of disease activity in patients with relapsing-remitting MS.
In April 2010, Provenge became the first dendritic cell vaccine in cancer treatment to be approved by the US Food and Drug Administration, and the agent is now used in the treatment of metastatic castration-resistant prostate cancer. Insights gleaned from this research are now being applied in the study of a potential vaccine for multiple sclerosis treatment and prevention.
In a study published in the journal Clinical Chemistry and Laboratory Medicine, investigators identified uric acid as a potential biomarker in the progression of multiple sclerosis disability.